BOULDER, Colo., June 4, 2018 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced updated results from the Phase 3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed median overall survival (mOS) was 33.6 months for patients treated with the combination of encorafenib and binimetinib compared to 16.9 months for patients treated with vemurafenib as …
Tag Archives: encorafenib
June, 2018
September, 2017
-
13 September
FDA to Review Array BioPharma’s NDAs for Binimetinib and Encorafenib for Advanced BRAF-Mutant Melanoma
BOULDER, Colo., Sept. 12, 2017 /PRNewswire/ — Array BioPharma (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Applications (NDAs) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, …
January, 2015
-
26 January
Array BioPharma Gains Rights to Novartis’ Cancer Candidate
BioPharma has struck a deal with Novartis Pharma AG for rights to an investigational cancer drug. Array recently announced that it has entered into a definitive agreement with Novartis to acquire worldwide rights to encorafenib (LGX818), Novartis’ BRAF inhibitor in development for treatment of skin and colorectal cancer. The deal …